Clinical Trial Update: A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating different doses of CagriSema for weight loss in adults with obesity. The study status is Active Not Recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• CagriSema (cagrilintide/semaglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Obesity | Phase 3 | Status: ACTIVE_NOT_RECRUITING